Full-Time
Quality Assurance Analyst
Posted on 9/9/2026
Aflac
10,001+ employees
Supplemental health and life insurance provider
Compensation Overview
$60k - $85k/yr
Windsor, CT, USA
Remote
Remote within the continental United States; occasional office visits may be requested based on business need.
Bachelor's
 Risk & Compliance (1) |
|---|
Get referred to Aflac
See people who can refer or advise you
- Knowledge of state and federal Family and Medical Leave Act regulations.
- Solid knowledge of regulatory compliance.
- Excellent verbal and written communication and interpersonal skills.
- Ability to interact and collaborate with internal partners, including leadership.
- Proficiency with Microsoft Office Suite.
- Strong analytical, problem-solving, and investigative skills.
- Exceptional attention to detail.
- Ability to learn in a fast-paced environment.
- Bachelor's degree in Healthcare, Business Administration, or a related field.
- Three or more years of job-related experience, or an equivalent combination of education and experience.
- Monitor quality indicators proactively and take steps to reduce deficiencies.
- Identify and correct process gaps within service channels and implement solutions to improve performance.
- Prepare periodic reports on quality volumes.
- Mitigate negative impacts and loss of business.
- Support project delivery by providing technical process expertise aligned with established practices.
- Conduct investigations and reviews of data practices to identify compliance issues and recommend actions.
- Independently collect and analyze operational data using standard tools to make recommendations supporting departmental decisions.
- Assess and evaluate project deliverables and processes to identify opportunities for improvement.
- Plan and conduct reviews of business data and metrics using standard methodologies to identify weaknesses and recommend actions to improve performance.
- Review and interpret information and advise internal clients on appropriate actions to comply with procedural and regulatory requirements.
- Maintain a document audit trail of activities to protect and support the organization and standardize business delivery.
- Perform other duties as required.
- Knowledge of medical disability management.
Aflac provides supplemental health and life insurance products to individuals and families, operating mainly in two regions: Aflac Japan and Aflac U.S. Its policies are designed to cover out-of-pocket costs from health events and income loss, including cancer, critical illness, accidents, hospital stays, and life events. These benefits are paid directly to policyholders to help manage medical expenses not fully covered by primary insurance. The products are distributed through a network of independent agents, brokers, and financial advisors, enabling a high-volume, low-premium model that supports a large, stable customer base and ongoing revenue. Japan is its largest market, and the company uses this broad distribution and scale to differentiate itself from competitors. The goal is to provide straightforward financial protection against unexpected health-related costs while expanding its presence in the U.S. and Japanese markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
Columbus, Georgia
Founded
1955
Get referred to Aflac
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 U.S. sales rose 2.6%, led by group voluntary and dental coverage.
- Aflac returned $1.3 billion in Q2 2026, reinforcing dividend and buyback credibility.
- Japan pretax margin reached 34.3% in Q2 2026, supporting ROE expansion.
What critics are saying
- Q2 2026 Japan sales fell 5.6%, exposing dependence on product launch timing.
- Persistency slipped to 92.7% in Q2 2026, hurting earned premiums and growth.
- If Japan lapses, FX pressure, and slower U.S. growth persist, valuation stalls.
What makes Aflac unique
- Aflac Japan keeps leading cancer and medical policies in force in 2026.
- Aflac’s 2026 product refresh, Miraito, Tsumitasu, and Anshin Palette, expands cross-selling.
- Aflac’s 2026 capital flexibility includes a shelf registration and regular yen funding.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Paid Holidays
Hybrid Work Options
Remote Work Options
Growth & Insights and Company News
6 month growth
↓ -2%1 year growth
↓ -2%2 year growth
↓ -2%Aflac's second quarter results disappointed investors despite meeting Wall Street expectations, with revenue declining 6.9% year-on-year to $4.22 billion. The insurance giant attributed the sales drop largely to difficult comparisons following last year's launch of its Miraito cancer insurance product in Japan. Chief Executive Daniel Amos said new Japanese offerings like Tsumitasu and Anshin Palette generated solid growth. US sales grew modestly, supported by group voluntary products and network dental and vision offerings. During the earnings call, analysts pressed management on several key issues. Questions focused on the sustainability of asset repositioning efforts, appetite for larger acquisitions, sequential declines in Japanese medical sales, and the impact of inflation on policy lapse rates. Amos said Aflac remains open to strategic acquisitions but will maintain discipline, favouring smaller deals that fit operationally and financially.
Aflac reported second-quarter revenue of $4.22 billion, meeting Wall Street expectations but declining 6.9% year on year. Adjusted earnings per share of $1.75 also met analyst estimates. The supplemental insurance provider attributed the revenue decline to tough comparisons in Japan following last year's cancer insurance product launch and shifting consumer preferences. However, CEO Daniel Amos highlighted solid growth from new offerings including Tsumitasu and Anshin Palette. In the US, group voluntary products and network dental and vision sales showed strength, with dental and vision product sales rising 47%. The company maintained expense discipline despite inflationary pressures. Looking ahead, Aflac plans to focus on product innovation in Japan, continued US group product momentum, and enhanced capital management. Management emphasised its commitment to dividend growth and share repurchases.
Aflac reported second-quarter revenue of $4.12 billion, missing analyst estimates of $4.23 billion and marking a 9.2% year-on-year decline. The supplemental insurance provider's adjusted earnings per share of $1.75 met expectations. The company's book value per share reached $60.35, beating estimates by 9.3% and showing 18.7% year-on-year growth. Pre-tax profit was $995 million, with a 24.2% margin. Chairman and CEO Daniel P. Amos highlighted solid earnings execution and new opportunities in Japan through products including Anshin Palette medical insurance and Miraito cancer insurance. In the US, Aflac is focusing on supplemental health products for employers. Over the past five years, Aflac's revenue has declined at a 5.1% annual rate, reflecting ongoing demand challenges.
Aflac Incorporated reported second quarter 2026 results with net earnings of $825 million, or $1.63 per diluted share, compared with $599 million, or $1.11 per diluted share a year ago. Total revenues decreased 1.0% to $4.1 billion. Adjusted earnings were $883 million, down 7.7% from $957 million in the prior year quarter. Adjusted earnings per diluted share decreased 1.7% to $1.75. The company returned $1.3 billion to shareholders through $983 million in share repurchases and $309 million in dividends. Chairman and CEO Daniel Amos highlighted successful product initiatives in Japan and focus on supplemental health products in the US. The board declared a third quarter dividend of $0.61 per share, payable on 1 September 2026 to shareholders of record on 19 August 2026.
Aflac has filed an omnibus shelf registration statement covering common stock, debt securities, warrants and other instruments, whilst launching its Fit Checks cancer screening awareness campaign with fashion designer Rachel Zoe. The campaign uses QR-enabled fashion pieces to link wearable design with cancer risk education. The moves demonstrate Aflac's strategy of combining capital markets flexibility with brand-building in preventive health. However, the initiatives don't materially change near-term earnings catalysts or key risks including declining Japanese premiums, currency volatility and investment income pressure. The company's second quarter 2026 earnings release, scheduled for 6-7 August, will provide insight into whether new products and digital initiatives are improving premium trends and margins in Japan and the US, Aflac's primary markets.